FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Opsens Inc. (« Opsens » or the « Corporation »)
750, Boul. du Parc-Technologique, Québec, QC Canada G1P 4S3

2. Date of Material Change

September 7, 2016.

3. News Release

A news release, in French and English versions, was issued through CNW Telbec on September 7, 2016, copies of which are attached hereto.

4. Summary of Material Change

Opsens announces the appointment of Mr Pat Mackin as a Director of the Company.

5. Full Description of Material Change

5.1 Full Description of Material Change

Opsens is pleased to announce the appointment of Mr. Pat Mackin as a Director of the Company.

Pat Mackin brings over 25 years of experience in the medical device industry. Since September 2014, Mr Mackin has been President and Chief Executive Officer of CryoLife, Inc. (NYSE:CRY) (“CryoLife”), a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac surgical procedures. CryoLife markets and sells products in more than 80 countries worldwide.

Before joining CryoLife, he was President of the Cardiac Rhythm Disease Management Division at Medtronic, Inc. (NYSE:MDT) ("Medtronic"). Previously, also at Medtronic, he held the positions of Vice President, Vascular, Western Europe where he launched the Company’s first drug-eluding stent called “Endeavour” and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic, Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent five years at Deknatel/Snowden-Pencer, Inc. in various sales and marketing roles and three years as an Officer in the U.S. Army. Mr. Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point.

On September 7, 2016, Opsens' Board of Directors approved the grant of 100,000 stock options to Pat Mackin, pursuant to Opsens' Stock Option Plan adopted by shareholders on January 18, 2016.

Under the provisions of Opsens' stock option plan, each stock option granted entitles the holder to subscribe to one Opsens' common share at the latest on September 6, 2021 at a price of $1.50 per share. The stock options granted allow the holder to subscribe immediately for common stock of Opsens.

5.1 Disclosure for Restructuring Transactions

Not applicable.

6. Reliance on Subsection 7.1(2) of Regulation 51-102

Not applicable.

7. Omitted Information

Not applicable.

8. Executive Officer

For additional information, please contact:
Mr. Thierry Dumas, CPA, CA
Chief Financial Officer
Phone: (418) 781-0333

9. Date of Report

November 3, 2016

Opsens Inc.

by: *(s) Thierry Dumas*
Thierry Dumas, Chief Financial Officer

OPSENS NOMME PAT MACKIN AU CONSEIL D'ADMINISTRATION

Québec, Québec, 7 septembre 2016 - Opsens inc. (TSXV:OPS) (OTCQX:OPSSF) ("Opsens" ou la "Société") est heureuse d'annoncer la nomination de M. Pat Mackin à titre d'administrateur de la Société.

"Nous sommes ravis de voir Pat, un chef de file renommé de l'industrie de l'instrumentation médicale se joindre à nous, au moment où nous passons d'une mise en marché contrôlée à une commercialisation de plus grande envergure. Nous pourrons compter sur son expertise à la tête de sociétés de premier plan dans le secteur cardiovasculaire," a déclaré Louis Laflamme, président et chef de la direction d'Opsens.

Pat Mackin apporte plus de 25 années d'expérience dans l'industrie des dispositifs médicaux. Depuis septembre 2014, il est président et chef de la direction de CryoLife, Inc. (NYSE :CRT) (**"**CryoLife**"**), un chef de file dans la fabrication, la transformation et la distribution de tissus vivants implantables et de dispositifs médicaux utilisés dans les interventions chirurgicales cardiaques. CryoLife vend des produits dans plus de 80 pays à travers le monde.

Avant de se joindre à CryoLife, il a été président de la division gestion des maladies du rythme cardiaque chez Medtronic, Inc. (NYSE :MDT) (**"**Medtronic**"**). Auparavant, également chez Medtronic, il a occupé les postes de vice-président, vasculaire, Europe de l'Ouest où il a lancé la première endoprothèse à élution médicamenteuse appelée « Endeavour » et vice-président et directeur général, unité d'affaires endovasculaire. Avant de se joindre à Medtronic, M. Mackin a travaillé pendant six ans chez Genzyme, Inc. (**"**Genzyme**"**) à titre de premier vice-président et directeur général de l'unité d'affaires de chirurgie cardiovasculaire et en tant que directeur des ventes, division des produits chirurgicaux. Avant de se joindre à Genzyme, M. Mackin a passé cinq ans chez Deknatel / Snowden-Pencer, Inc. dans divers rôles dans le domaine des ventes et du marketing et trois ans comme officier dans l'armée des États-Unis. M. Mackin a reçu un MBA de la Kellogg Graduate School of Management de la Northwestern University et est diplômé de l'Académie militaire américaine de West Point.

Octroi d'options d'achat d'actions

Le Conseil d'administration d'Opsens a autorisé, le 7 septembre 2016, l'octroi de 100 000 options d'achat d'actions à Pat Mackin, conformément au régime d'options d'achat d'actions d'Opsens adopté par les actionnaires le 18 janvier 2016.

En vertu des dispositions du régime d'options d'achat d'actions, chacune des options octroyées permettra au détenteur de souscrire à une action ordinaire d'Opsens au plus tard le 6 septembre 2021 à un prix égal à 1,50 $ par action. Les options octroyées permettront au détenteur de souscrire immédiatement aux actions ordinaires d'Opsens.

À propos d'Opsens inc. (www.opsens.com ou www.opsensmedical.com) La Société se concentre principalement sur la mesure de la FFR dans le marché de la cardiologie interventionnelle. Opsens offre un fil guide optique de mesure de pression (OptoWire) qui vise à améliorer les résultats cliniques chez les patients atteints de maladies coronariennes. Opsens opère également dans le secteur industriel où elle développe, fabrique et installe des solutions de mesure innovantes qui utilisent la fibre optique pour des applications critiques comme la surveillance des puits de pétrole et plusieurs autres applications industrielles exigeantes.

Les énoncés prospectifs contenus dans ce communiqué de presse comportent des risques connus et inconnus, des incertitudes et d'autres facteurs pouvant modifier de manière appréciable les résultats, le rendement et les réalisations d'Opsens par rapport aux résultats, au rendement et aux réalisations qui y sont exprimés ou implicites.

La Bourse de croissance TSX et son fournisseur de services de règlementation (au sens attribué à ce terme dans les politiques de la Bourse de croissance TSX) n'assument aucune responsabilité quant à la pertinence ou à l'exactitude du présent communiqué de presse.

-30-

Information :

Thierry Dumas, CPA, CA, chef de la direction financière, 418.781.0333

Louis Laflamme, CPA, CA, président et chef de la direction, 418.781.0333

OPSENS APPOINTS PAT MACKIN TO ITS BOARD OF DIRECTORS

Quebec City, Quebec, September 7, 2016 – Opsens Inc. ("Opsens") (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce the appointment of Mr Pat Mackin as a Director of the Company.

"We are delighted to see Pat, a renowned leader in the medical device industry, join us. His expertise as head of leading companies in the cardiovascular space will be valuable as we step up from limited market release to a wider one," said Louis Laflamme, President and CEO of Opsens.

Pat Mackin brings over 25 years of experience in the medical device industry. Since September 2014, Mr Mackin has been President and Chief Executive Officer of CryoLife, Inc. (NYSE:CRY) ("CryoLife"), a leader in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac surgical procedures. CryoLife markets and sells products in more than 80 countries worldwide.

Before joining CryoLife, he was President of the Cardiac Rhythm Disease Management Division at Medtronic, Inc. (NYSE:MDT) ("Medtronic"). Previously, also at Medtronic, he held the positions of Vice President, Vascular, Western Europe where he launched the Company's first drug-eluding stent called "Endeavour" and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic, Mr Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr Mackin spent five years at Deknatel/Snowden-Pencer, Inc. in various sales and marketing roles and three years as an Officer in the U.S. Army. Mr Mackin received an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point.

GRANT OF STOCK OPTIONS

On September 7, 2016, Opsens' Board of Directors approved the grant of 100,000 stock options to Pat Mackin, pursuant to Opsens' Stock Option Plan adopted by shareholders on January 18, 2016.

Under the provisions of Opsens' stock option plan, each stock option granted entitles the holder to subscribe to one Opsens' common share at the latest on September 6, 2021 at a price of $1.50 per share. The stock options granted allow the holder to subscribe immediately for common stock of Opsens.

About Opsens Inc. (www.opsens.com or www.opsensmedical.com)

Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other demanding industrial applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Thierry Dumas, CPA, CA, Chief Financial Officer, 418.781.0333
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333